Geriatric Assessment Center, Health Department, Iberoamerican University, Mexico City, Mexico.
Pediatric Obesity Clinic and Wellness Unit, Hospital General de México "Dr. Eduardo Liceaga", Mexico City, Mexico.
Front Endocrinol (Lausanne). 2023 Aug 10;14:1192236. doi: 10.3389/fendo.2023.1192236. eCollection 2023.
Sarcopenia is a highly prevalent disease associated with adverse outcomes such as falls, disability, and death. The current international consensuses agree that muscle strength, muscle mass, and gait speed must be included in the definition. However, these proposed criteria require objective measurements that are not available for most populations. Since the timely identification of sarcopenia is a priority, several subjective screening scales have been developed; however, they have some limitations due to their low sensitivity. The objective of this work was to develop and validate SARCO-GS, a new short scale to screen sarcopenia that is affordable, easy, and accessible for all clinical care settings.
The development of the SARCO-GS included four stages: (1) Review and analysis of documentary sources, (2) Contextualization of the theoretical model of sarcopenia, (3) Scale conformation, and (4) Reliability and validity analyses. SARCO-GS was validated in the FraDySMex study, which is a longitudinal cohort of community-dwelling adults.
In the studied population (n=852), the average age was 68.9 years (SD 10.21) and 80.1% of the participants were women. SARCO-GS is a seven-item scale with an innovative structure that included five subjective questions (gait speed, muscular strength, muscle mass) and two measurements of muscular strength and muscle mass (Chair stand test and calf circumference). The results regarding criterion validity showed that the cut-off point ≥ 3 had good sensitivity (77.68%) versus the EWGSOP2 consensus, with an adequate Area Under the Receiver Operating Characteristic (AUC) (0.73), in addition to showing higher values of sensitivity and AUC than SARC-F and SARC-CalF using as reference the same consensus. Furthermore, SARCO-GS presented good predictive validity for functional dependence (HR=2.22, p=0.046) and acceptable correlation with other related measurements (construct validity). Regarding reliability, the scale showed acceptable internal reliability (correlation between items and total score: 0.50 to 0.70). After the validation analysis, the scale was adapted to English.
The SARCO-GS is a novel scale to screen sarcopenia with high sensitivity, good construct, predictive validity, and internal reliability that may be useful for health professionals in different clinical settings and for clinical research.
肌少症是一种高发疾病，与跌倒、残疾和死亡等不良后果相关。目前国际共识认为，肌肉力量、肌肉质量和步态速度必须包含在定义中。然而，这些提出的标准需要客观的测量，而大多数人群无法进行这些测量。由于及时识别肌少症是当务之急，因此已经开发了几种主观筛查量表；然而，由于其敏感性较低，它们存在一些局限性。这项工作的目的是开发和验证 SARCO-GS，这是一种新的用于筛查肌少症的简短量表，价格实惠、简单易用，适用于所有临床护理环境。
SARCO-GS 的开发包括四个阶段：（1）文献来源的回顾和分析，（2）肌少症理论模型的情境化，（3）量表构建，以及（4）可靠性和有效性分析。SARCO-GS 在 FraDySMex 研究中进行了验证，该研究是一项社区居住成年人的纵向队列研究。
在所研究的人群（n=852）中，平均年龄为 68.9 岁（SD 10.21），80.1%的参与者为女性。SARCO-GS 是一个由七个项目组成的量表，具有创新的结构，包括五个主观问题（步态速度、肌肉力量、肌肉质量）和两个肌肉力量和肌肉质量的测量（椅子站立测试和小腿围度）。关于标准效度的结果表明，截点≥3 对 EWGSOP2 共识具有良好的敏感性（77.68%），同时具有适当的接收者操作特征曲线下面积（AUC）（0.73），此外，与 SARC-F 和 SARC-CalF 相比，使用相同的共识作为参考，SARCO-GS 具有更高的敏感性和 AUC 值。此外，SARCO-GS 对功能依赖具有良好的预测效度（HR=2.22，p=0.046），并且与其他相关测量具有可接受的相关性（结构效度）。关于可靠性，该量表显示出可接受的内部可靠性（项目与总分之间的相关性：0.50 至 0.70）。经过验证分析后，该量表被改编为英文。
SARCO-GS 是一种新颖的筛查肌少症的量表，具有高敏感性、良好的结构、预测有效性和内部可靠性，对于不同临床环境的健康专业人员和临床研究可能是有用的。
